|
Market Closed -
Nasdaq
21:00:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 90.78 USD | +9.10% |
|
+26.51% | +10.87% |
| 09-04 | Tarsus Pharmaceuticals Shares Rise After Closing Alkeus Pharmaceuticals Acquisition | MT |
| 09-04 | Tarsus Pharmaceuticals Closes Acquisition of Alkeus Pharmaceuticals | MT |
Company Valuation: Tarsus Pharmaceuticals, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 465.2 | 391 | 670.4 | 2,117 | 3,476 | 3,984 | - | - |
| Change | - | -15.95% | 71.44% | 215.74% | 64.21% | 14.61% | - | - |
| Enterprise Value (EV) | 465.2 | 391 | 472.1 | 1,894 | 3,476 | 3,984 | 3,984 | 3,984 |
| Change | - | -15.95% | 20.74% | 301.19% | 83.5% | 14.61% | 0% | 0% |
| P/E | -33.6x | -5.82x | -4.38x | -18x | -51.5x | -42.6x | 39x | 18.8x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | -0x | -0.1x | 0.5x | 1.1x | -1.2x | -0x | 0x |
| Capitalization / Revenue | 8.16x | 15.1x | 38.4x | 11.6x | 7.7x | 5.58x | 4.31x | 3.62x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 5.58x | 4.31x | 3.62x |
| EV / EBITDA | -0x | -0x | -0x | -0x | -0x | -43x | 26.1x | 9.7x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -38.7x | 30.6x | 13.1x |
| EV / FCF | 0x | - | - | - | -0x | -34.8x | 114x | 18x |
| FCF Yield | 0.68% | - | - | - | -0.64% | -2.88% | 0.88% | 5.54% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.67 | -2.52 | -4.62 | -3.07 | -1.59 | -2.132 | 2.325 | 4.817 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 57.03 | 25.82 | 17.45 | 183 | 451.4 | 713.6 | 925.3 | 1,099 |
| EBITDA 1 | -11.84 | -62.39 | -142.3 | -119.8 | -69.15 | -92.72 | 152.4 | 410.8 |
| EBIT 1 | -12.16 | -62.71 | -143.2 | -120.6 | -70.97 | -103 | 130.1 | 303.8 |
| Net income 1 | -13.83 | -62.09 | -135.9 | -115.6 | -66.42 | -95.74 | 115.9 | 261.7 |
| Net Debt | - | - | -198.3 | -222.5 | - | - | - | - |
| Reference price 2 | 22.50 | 14.66 | 20.25 | 55.37 | 81.88 | 90.78 | 90.78 | 90.78 |
| Nbr of stocks (in thousands) | 20,677 | 26,672 | 33,105 | 38,227 | 42,449 | 43,883 | - | - |
| Announcement Date | 14/03/22 | 13/03/23 | 27/02/24 | 25/02/25 | 23/02/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -42.58x | - | - | -.--% | 3.98B | |
| 19.17x | 4.48x | 10.55x | 0.47% | 82.65B | |
| 20.62x | 4.39x | 13.64x | 2.39% | 60.24B | |
| -17.31x | 25.92x | -17.11x | -.--% | 58.11B | |
| 35.25x | 12x | 23.01x | -.--% | 49.68B | |
| 21.03x | 4.65x | 13.26x | 0.69% | 46.66B | |
| 38.13x | 3.6x | 13.71x | -.--% | 32.63B | |
| 56.56x | 3.61x | 27.99x | -.--% | 25.69B | |
| 68.2x | 7.25x | 44.11x | -.--% | 22.73B | |
| 23.84x | 5.1x | 13.28x | -.--% | 16.51B | |
| Average | 22.29x | 7.89x | 15.83x | 0.35% | 39.89B | |
| Weighted average by Cap. | 22.63x | 8.64x | 12.28x | 0.54% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- TARS Stock
- Valuation Tarsus Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
